Porous metal–organic-framework nanoscale carriers as a potential platform for drug delivery and imaging
Source abstract
Abstract
In the domain of health, one important challenge is the efficient delivery of drugs in the body using non-toxic nanocarriers. Most of the existing carrier materials show poor drug loading (usually less than 5 wt% of the transported drug versus the carrier material) and/or rapid release of the proportion of the drug that is simply adsorbed (or anchored) at the external surface of the nanocarrier. In this context, porous hybrid solids, with the ability to tune their structures and porosities for better drug interactions and high loadings, are well suited to serve as nanocarriers for delivery and imaging applications. Here we show that specific non-toxic porous iron(III)-based metal-organic frameworks with engineered cores and surfaces, as well as imaging properties, function as superior nanocarriers for efficient controlled delivery of challenging antitumoural and retroviral drugs (that is, busulfan, azidothymidine triphosphate, doxorubicin or cidofovir) against cancer and AIDS. In addition to their high loadings, they also potentially associate therapeutics and diagnostics, thus opening the way for theranostics, or personalized patient treatments.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Covalent Organic Framework Applications · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2, 751–760 (2007).
2. Couvreur, P., Gref, R., Andrieux, K. & Malvy, C. Nanotechnology for drug delivery: Applications to cancer and autoimmune diseases. Prog. Solid State Chem. 34, 231–235 (2006).10.1016/j.progsolidstchem.2005.11.009 ↗
3. Gref, R. et al. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600–1603 (1994).10.1126/science.8128245 ↗
4. Gabizon, A. Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet. Clin. Cancer Res. 7, 223–225 (2001).
5. Sheikh Hasan, A. et al. Effect of the microencapsulation of nanoparticles on the reduction of burst release. Int. J. Pharm. 344, 53–61 (2007).10.1016/j.ijpharm.2007.05.066 ↗
6. Horcajada, P. et al. Metal–organic frameworks as efficient materials for drug delivery. Angew. Chem. Int. Ed. 45, 5974–5978 (2006).10.1002/anie.200601878 ↗
7. Horcajada, P. et al. Flexible porous metal–organic frameworks for a controlled drug delivery. J. Am. Chem. Soc. 130, 6774–6780 (2008).10.1021/ja710973k ↗
8. Hinks, N. J., McKinlay, A. C., Xiao, B., Wheatley, P. S. & Morris, R. E. Metal organic frameworks as NO delivery materials for biological applications. Microporous Mesoporous Mater. 10.1016/j.micromeso.2009.04.031 (2009) (in the press).10.1016/j.micromeso.2009.04.031 ↗
9. Xiao, B. et al. Chemically blockable transformation and ultraselective low-pressure gas adsorption in a non-porous metal organic framework. Nature Chem. 1, 289–294 (2009).10.1038/nchem.254 ↗
10. Rieter, W. J., Pott, K. M., Taylor, K. M. L. & Lin, W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J. Am. Chem. Soc. 130, 11584–11585 (2008).10.1021/ja803383k ↗
11. Rieter, W. J., Taylor, K. M. L., An, H. & Lin, W. Nanoscale metal–organic frameworks as potential multimodal contrast enhancing agents. J. Am. Chem. Soc. 128, 9024–9025 (2006).10.1021/ja0627444 ↗
12. Taylor, K. M. L., Jin, A. & Lin, W. Surfactant-assisted synthesis of nanoscale gadolinium metal–organic-framework for potential multimodal imaging. Angew. Chem. Int. Ed. 47, 7722–7725 (2008).10.1002/anie.200802911 ↗
13. Taylor, K. M. L., Rieter, W. J. & Lin, W. Manganese-based nanoscale metal–organic frameworks for magnetic resonance imaging. J. Am. Chem. Soc. 130, 14358–14359 (2008).10.1021/ja803777x ↗
14. Férey, G. Hybrid porous solids: Past, present, future. Chem. Soc. Rev. 37, 191–241 (2008).10.1039/B618320B ↗
15. Jhung, S. H. et al. Microwave synthesis of chromium terephthalate MIL-101 and its benzene sorption ability. Adv. Mater. 19, 121–124 (2007).10.1002/adma.200601604 ↗
16. Hermes, S. et al. Selective nucleation and growth of metal–organic open framework thin films on patterned COOH/CF3-terminated self-assembled monolayers on Au(111). J. Am. Chem. Soc. 127, 13744–13745 (2005).10.1021/ja053523l ↗
17. Scherb, C. & Bein, T. Directing the structure of metal–organic frameworks by oriented surface growth on an organic monolayer. Angew. Chem. Int. Ed. 47, 5777–5779 (2008).10.1002/anie.200704034 ↗
18. Llewellyn, P. L. et al. High uptakes of CO2 and CH4 in mesoporous metal–organic-frameworks MIL-100 and MIL-101. Langmuir 24, 7245–7250 (2008).10.1021/la800227x ↗
19. Horcajada, P., Serre, C., Gref, R., Férey, G. & Couvreur, P. Nanoparticules hybrides organiques inorganiques à base de carboxylates de fer, PCT applications PCT/FR2008/001366, 01 October 2008.
20. Horcajada, P., Serre, C., Gref, R., Férey, G. & Couvreur, P. Solides hybrides organique–inorganique à surface modifiée, PCT applications PCT/FR2008/001367, 01 October 2008.
21. Férey, G. & Serre, C. Large breathing effects in three-dimensional porous hybrid matter: Facts, analyses, rules and consequences. Chem. Soc. Rev. 38, 1380–1399 (2009).10.1039/b804302g ↗
22. Serre, C. et al. Role of solvent-host interactions that lead to very large swelling of hybrid frameworks. Science 315, 1828–w1831 (2007).10.1126/science.1137975 ↗
23. Serre, C. et al. A route to the synthesis of trivalent transition-metal porous carboxylates with trimeric secondary building units. Angew. Chem. Int. Ed. 43, 6285–6289 (2004).10.1002/anie.200454250 ↗
24. Surblé, S. et al. A new isoreticular class of metal–organic-frameworks with the MIL-88 topology. Chem. Commun. 3, 284–286 (2006).10.1039/B512169H ↗
25. Whitfield, T. R., Wang, X., Liu, L. & Jacobson, A. J. Metal-organic frameworks based on iron oxide octahedral chains connected by benzenedicarboxylate dianions. Solid State Sci. 7, 1096–1103 (2005).10.1016/j.solidstatesciences.2005.03.007 ↗
26. Horcajada, P. et al. Synthesis and catalytic properties of MIL-100(Fe), an iron(III) carboxylate with large pores. Chem. Commun. 27, 2820–2822 (2007).10.1039/B704325B ↗
27. Bauer, S. et al. High-throughput assisted rationalization or the formation of metal–organic framework in the iron(III) aminoterephthalate solvothermal system. Inorg. Chem. 47, 7568–7576 (2008).10.1021/ic800538r ↗
28. Gref, R. et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 16, 215–233 (1995).10.1016/0169-409X(95)00026-4 ↗
29. Sheftel, V. O. Indirect Food Additives and Polymers: Migration and Toxicology 148–154 (Lewis Publishers, 2000).10.1201/9781482293821 ↗
30. (2008).
31. (2008).
32. (2008).
33. Mosmann, T. Rapid colourimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983).10.1016/0022-1759(83)90303-4 ↗
34. Soma, C. E. et al. Drug delivery to resistance tumors: The potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 68, 283–289 (2000).10.1016/S0168-3659(00)00269-8 ↗
35. Vassal, G. et al. Is 600 mg m−2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79, 2475–2479 (1992).10.1182/blood.V79.9.2475.2475 ↗
36. Vassal, G. et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother. Pharmacol. 24, 386–390 (1989).
37. Slattery, T. et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 16, 31–42 (1995).
38. Layre, A., Gref, R., Richard, J., Requier, D. & Couvreur, P. Nanoparticules polymériques composites, FR 04 07569, 7 July 2004.
39. Hassan, Z., Nilsson, C. & Hassan, M. Liposomal busulphan: Bioavailability and effect on bone marrow in mice. Bone Marrow Transplant. 22, 913–918 (1998).10.1038/sj.bmt.1701458 ↗
40. Madden, T. et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule. Biol. Blood Marrow Transplant. 13, 56–64 (2007).10.1016/j.bbmt.2006.08.037 ↗
41. Thierry, A. R. et al. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 7, 572–579 (1993).10.1096/fasebj.7.6.8097173 ↗
42. Loke, S. L. et al. Characterization of oligonucleotide transport into living cells. Proc. Natl Acad. Sci. USA 86, 3474–3478 (1989).10.1073/pnas.86.10.3474 ↗
43. Kukhanova, M. et al. Design of anti-HIV compounds: From nucleoside to nucleoside 5′-triphosphate analogs. Problems and perspectives. Curr. Pharm. Des. 6, 585–598 (2000).10.2174/1381612003400687 ↗
44. Hillaireau, H. et al. Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules. Int. J. Pharm. 324, 37–42 (2006).10.1016/j.ijpharm.2006.07.006 ↗
45. Roch, A. et al. Theory of proton relaxation induced by superparamagnetic particles. J. Chem. Phys. 110, 5403–5411 (1999).10.1063/1.478435 ↗
46. Muller, R. N. et al. in The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging (eds Merbach, A. E. & Tóth, É.) 417–435 (Wiley, 2001).